Pharmaceutical Technology on MSN
R1 Therapeutics raises $77.5M to progress AP306 for hyperphosphatemia
R1 plans to initiate a Phase IIb study of AP306 later this year.
Series A co-led by Abingworth, DaVita Venture Group, and F-Prime with participation from Curie.Bio, SymBiosis, and U.S. Renal CarePartnership ...
R1 Therapeutics is debuting with an oversubscribed $77.5 million series A financing aimed at advancing its first-in-class ...
The startup believes a pill it licensed from a Chinese biotech company could be more potent, and convenient to take, than existing treatments for a common complication of chronic kidney disease.
Obesity is widely known for increasing the risk of diabetes and cardiovascular disease, but its damaging effects on the skeleton are often overlooked. Excess body fat can disrupt bone metabolism, ...
The arterial vasculature is the second most frequently calcified structure in the human body after the skeleton. Calcification of the aorta and aortic valves occurs in most individuals in westernized ...
On October 22, 2007, the US Food and Drug Administration (FDA) granted marketing approval to Genzyme for Renvela, a new treatment for the control of serum phosphorus in patients with chronic kidney ...
LOS ALTOS, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics (UNCY), Inc. , a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results